Monday, 27 August 2018

Dentifrices – The Best Solution for Xerostomia

Xerostomia (dry mouth) is a symptom of radiation-induced therapy or caused due to a side-effect of therapeutic medicines. The symptom is also seen in Sjögren’s syndrome, an autoimmune disease. The absence of saliva causes difficulty in chewing and swallowing food. If left untreated, it can lead to oral health problems and bad odor. It can be treated with salivary substitutes or dentist-recommended medicine to counter the effects of the symptom. Types of products used in treating dry mouth are dentifrices, salivary substitutes, and salivary stimulants.

Dentifrices to Witness the Maximum Demand

Among the product types, dentifrices segment accounted for a large revenue share in 2016 owing to the easy availability of teeth cleansing agents at affordable prices. Emphasis on oral hygiene and commercialization of toothpastes are the key factors driving the demand for dentifrices.

The salivary stimulants segment is expected to have a robust growth during the forecast period (from 2018 to 2025) due to the presence of various stimulants such as lozenges and mints. The advances in stimulants to prevent bacterial growth and bad odor are projected to increase the demand for this segment. For instance, TheraBreath Dry Mouth Oral Rinse launched by TheraBreath in April 2017 can treat the symptom by producing saliva with the help of moisturizing enzymes. It is particularly helpful for patients above the age of 60 that suffer from the symptom due to various medications.

Market Outlook
The global xerostomia (dry mouth) therapeutics market is predicted to reach USD 796.1 million by 2025, according to a report by Grand View Research, Inc. It is expected to exhibit a CAGR of 3.2 % from 2018 to 2025 owing to various awareness programs highlighting the seriousness of the disease. Moreover, the availability of cost-effective drugs and prescriptions may also augment the market demand in the next few years. Some of the key companies in this market include Acacia Pharma; Lupin Pharmaceuticals, Inc.; Hikma Pharmaceuticals LLC; and GlaxoSmithKline plc.

Read more

No comments: